IDXX:NGS-IDEXX Laboratories Inc.

EQUITY | Medical Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 200.87

Change

0.00 (0.00)%

Market Cap

USD 10.75B

Volume

0.80M

Analyst Target

USD 247.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

IDEXX Laboratories Inc develops, manufactures and distributes products and provide services for companion animal veterinary, livestock and poultry, dairy and water testing markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-20 )

Largest Industry Peers for Medical Diagnostics & Research

ETFs Containing IDXX

PETZ:LSE 8.59 % 0.00 %

N/A

N/A
KATZ:XETRA 8.16 % 0.00 %

N/A

N/A
PETZ:SW 8.16 % 0.00 %

N/A

N/A
UMDV:SW iShares US Medical Device.. 4.19 % 0.00 %

-0.03 (0%)

USD 0.18B
WHCS:SW iShares MSCI World Health.. 2.69 % 0.00 %

N/A

USD 1.07B
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

-0.25 (0%)

USD 5.55B
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

-0.98 (0%)

USD 0.15B
JMIN 0.00 % 0.12 %

N/A

N/A
YXM.A:CA 0.00 % 1.49 %

N/A

N/A
YXM.D:CA 0.00 % 1.53 %

N/A

N/A
JUMF:XETRA 0.00 % 0.00 %

N/A

N/A
LCG Sterling Capital Focus Eq.. 0.00 % 0.00 %

-0.22 (0%)

USD 0.07B
PFUT Putnam Sustainable Future.. 0.00 % 0.00 %

-0.08 (0%)

USD 0.24B
JUMF:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.98% 39% F 51% F
Dividend Return N/A N/A N/A N/A F
Total Return 7.98% 39% F 51% F
Trailing 12 Months  
Capital Gain 11.21% 59% D- 82% B
Dividend Return N/A N/A N/A N/A F
Total Return 11.21% 57% F 81% B-
Trailing 5 Years  
Capital Gain 253.71% 81% B- 95% A
Dividend Return N/A N/A N/A N/A F
Total Return 253.71% 81% B- 95% A
Average Annual (5 Year Horizon)  
Capital Gain 36.99% 89% A- 90% A-
Dividend Return 36.99% 89% A- 90% A-
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 28.92% 69% C- 45% F
Risk Adjusted Return 127.89% 95% A 95% A
Market Capitalization 10.75B 98% N/A 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 50.40 15% 7%
Price/Book Ratio -418.48 100% 100%
Price / Cash Flow Ratio 11.57 8% 6%
Price/Free Cash Flow Ratio 62.19 8% 6%
Management Effectiveness  
Return on Equity -902.48% 3% 1%
Return on Invested Capital 83.32% 98% 98%
Return on Assets 21.10% 94% 97%
Debt to Equity Ratio -17,580.50% 100% 100%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Negative Book Value

The company has negative book value.